mobile menu
Long-term effect of intensive glucose control in type 2 diabetes: The ACCORD International Ongoing (ACCORDION) Study
04-Dec-15
Del Prato, Prof. S.
Chinese consensus on management of postprandial hyperglycaemia in type 2 diabetes
02-Dec-15
Li, MD Y.
What will the Acarbose Cardiovascular Evaluation (ACE) trial tell us?
02-Dec-15
Holman, Prof. R.
Addressing the type 2 diabetes pandemic: the need for transformational thinking and innovative treatments (Archive)
23-Sep-13
Mauricio, Dr. D.
New evidence from GLP-1 receptor agonist studies: their role in diabetes care (Archive)
23-Sep-13
Nauck, Prof. M. A.
Clinical experience: how can GLP-1 receptor agonists improve daily life for patients? (Archive)
23-Sep-13
Vilsboll, Dr. T.
An innovative treatment target for managing type 2 diabetes: evidence from SGLT-2 inhibitor trials (Archive)
23-Sep-13
Hadjadj, Dr. S.
Clinical experience with dapagliflozin (Archive)
23-Sep-13
Rossing, Dr. P.
From UKPDS to SAVOR: the evolving landscape of CV outcomes studies in type 2 diabetes (Archive)
23-Sep-13
Barnett, Prof. A.
Introducing the latest CV safety studies in type 2 diabetes (Archive)
23-Sep-13
Mannucci, Dr. E.
Key findings from the SAVOR study: the effects of saxagliptin (Archive)
23-Sep-13
Darius, Prof. Dr. H.
The potential impact of SAVOR on clinical practice (Archive)
23-Sep-13
Mathieu, Prof. Ch.
Summary (Archive)
23-Sep-13
Nauck, Prof. M. A.
How could we transform treatment in type 2 diabetes: which approach, when and for whom? (Archive)
23-Sep-13
Nauck, Prof. M. A. / Barnett, Prof. A. / Vilsboll, Dr. T. / Hadjadj, Dr. S. / Rossing, Dr. P. / Mannucci, Dr. E. / Darius, Prof. Dr. H. / Mathieu, Prof. Ch.
The ongoing challenge of type 2 diabetes: why we still need new approaches (Archive)
01-Oct-12
Khunti, Prof. K.
A novel way of treating type 2 diabetes: removing excess glucose through SGLT2 inhibition (Archive)
01-Oct-12
Fioretto, Prof. P.
Stepping up – why insulin therapy in people with type 2 diabetes is often initiated too late and what we need to do against it: The Australian perspective (Archive)
01-Oct-12
O’Neal, Dr. D.
Question 2: Using FPG to safely titrate long acting basal insulin? (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 8: Nutrition – any changes warranted, especially any supplementation with PUFAs? (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
The ORIGIN-Trial: Conclusion (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 7: Long acting insulins firstline therapy: What are the risks? (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 6: Screening for IGT? (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 5: Targeting FPG vs postprandial glucose? (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 4: Specific benefits of early insulinisation? (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 3: Long acting insulins firstline therapy versus other established options (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
Question 1: Targets of glycemic control (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
The ORIGIN-Trial (Archive)
11-Jun-12
Standl, Prof. E. / Hanefeld, Prof. M.
The need for individualized medicine in diabetes (Archive)
06-Dec-11
Ceriello, Prof. A.
Statin and RAAS inhibitor for every diabetic patient? (Archive)
06-Dec-11
Standl, Prof. E.
Self-monitoring of blood glucose: Impact on CV risk in diabetes (Archive)
06-Dec-11
Schnell, Prof. O.
Linagliptin: a new alternative in DPP-4 inhibition (Archive)
06-Dec-11
Gallwitz, Prof. J. B.
Sleep-disordered breathing and cardio-metabolic disease (Archive)
29-Oct-11
Wilding, Prof. J.
Impact of declining renal function on treatment choice in diabetes (Archive)
12-Sep-11
Groop, Prof. P.-H.
Setting a course for the future (Archive)
12-Sep-11
Aronson, Dr. R.
Going beyond conventional therapies: an update on DPP-4 inhibition (Archive)
12-Sep-11
Holst, Prof. J. J.
A different DPP-4 inhibitor (Archive)
12-Sep-11
Barnett, Prof. A.
New clinical challenges and new opportunities: recent developments in type 2 diabetes in perspective (Archive)
12-Sep-11
Ceriello, Prof. A.
The diabetes pandemic: a Portuguese perspective (Archive)
12-Sep-11
Raposo, Prof. J. F.
Case presentation and interactive discussion (Archive)
12-Sep-11
Vora, Prof. J.
Saxagliptin: now and beyond (Archive)
12-Sep-11
Jacob, Prof. S.
Case presentation and interactive discussion (Archive)
12-Sep-11
Vora, Prof. J.
Overcoming barriers now in successful treatment of type 2 diabetes (Archive)
12-Sep-11
Del Prato, Prof. S.
Why we should be treating to succeed (Archive)
20-Oct-10
Del Prato, Prof. S.
A review of treatment satisfaction and quality of life in people with type 2 diabetes (Archive)
20-Oct-10
de Pablos, Prof. Pedro
Latest insights on incretin-based treatments (Archive)
20-Oct-10
Holst, Prof. J. J.
Reducing daily glucose peaks and valleys for comprehensive glycaemic control: a clinical perspective (Archive)
20-Oct-10
Ceriello, Prof. A.
New data on the emerging role of saxagliptin in type 2 diabetes (Archive)
20-Oct-10
Jacob, Prof. S.
Is there a place for obstructive sleep apnoea screening in the Diabetes Clinic? (Archive)
20-Sep-10
Avignon, Prof. A.
Structured SMBG: Improved Glycemic Control in NIT T2D Patients - Final Results of the STeP Study (Archive)
20-Sep-10
Polonsky, MD W. H.
Structured SMBG: Study Rationale and Design of the STeP Study (Archive)
20-Sep-10
Fisher, PhD L.
Structured SMBG in NIT T2D Patients: The European Perspective (Archive)
20-Sep-10
Trovati, Prof. M.
Cardio-metabolic interactions and side effects of multifactorial risk management (Archive)
10-Apr-10
Standl, Prof. E.
Cardio-metabolic interactions and side effects of multifactorial risk management (Archive)
10-Apr-10
Standl, Prof. E.
Discussion (Archive)
18-Sep-07
Standl, Prof. E., Vilsbøll, Dr. T., Nauck, Prof., M.